LONDON, 10 July 2008 – Institutional stockbroker and investment bank, Panmure Gordon & Co, is pleased to announce it has led a capital raising totalling £2.7m for specialist drug discovery and development company, ImmuPharma.

ImmuPharma is principally involved in the development of long-term treatments for Lupus, a life-threatening auto immune disease, as well as an anti-cancer drug. The funds will be used continue the development of the firm’s clinical and pre-clinical pipelines.

Media enquiries:
Nathaniel Webb
Global Communications Manager
Tel: +44 (0)20 7614 8333

About the Panmure Gordon Group
Founded in 1876, Panmure Gordon & Co (PMR.L) is a leading independent mid-cap investment bank based in London. Encompassing its US franchise, ThinkPanmure LLC, the Group employs approximately 300 professionals across the US, the UK and Nyon, Switzerland, offering a blend of transatlantic financial services including research, sales and trading, wealth management and asset management.